POS1442 THE SUBGROUP OF ACPA-NEGATIVE RHEUMATOID ARTHRITIS PATIENTS ACHIEVING SUSTAINED DMARD-FREE REMISSION IS CHARACTERIZED BY A DIFFERENT RESPONSE IN SEROLOGICAL MARKERS WITHIN THE FIRST YEAR OF DMARD-INITIATION

Background: Whilst ~40% of ACPA-negative RA-patients achieve sustained DMARD-free remission (SDFR; the absence synovitis after DMARD-cessation), biological pathways involved in SDFR-development are incompletely understood. Previously, high baseline levels MMP-3, SAA and CRP were found achieving SDFR. Differences biomarker might reflect distinct underlying leading towards disease resolution this subgroup RA-patients. Subsequently, course specific biomarkers treatment-initiation could attain more insight understanding RA. Objectives: We explored whether response increase Methods: One-hundred-thirty-one consecutive studied on during (median) 7.2-years follow-up. Twelve (SAA/CRP/MMP-1/MMP-3/resistin/leptin/IL-6/TNF-R1/YKL-40/EGF/VEGF/VCAM-1) measured at diagnosis 1-, 2-years DMARD-initiation compared between patients not To extend previous findings levels, correlations change within year-1 determined using spearman’s rho (ρ). Results: that achieved SDFR (n=63) characterized by a stronger decline MMP-1, first 12-months DMARD-start, to MMP-1 MMP-3 declined 1.30-times (95%CI; 1.08-1.57) 1.44-times 1.00-2.06) SDFR-patients. In CRP, was 2.12-times 1.08-4.14) 2.24-times 1.16-4.35) stronger. Baseline strongly correlated with 12-months; ρ -0.6991, -0.9205 respectively -0.9008. strongest year DMARD-initiation. Conclusion: The higher serological Because expressed fibroblast-like synoviocytes, these cells may differ resolution; molecular studies synovial tissue be next step. Disclosure Interests: None declared